Abstract
Next Generation Sequencing (NGS) is a current trend in care for leukemic patients. It is used from diagnosis through monitoring of the course of the disease to the indication of the proper treatment.
In myelodysplastic syndrome (MDS), the identification of many previously undescribed mutations has been a major benefit of this technology, but their clinical use is still under investigation. The following text will describe how NGS can be used to improve care for MDS patients.
On the other hand, the limits of this technology will be mentioned too. Moreover, genetic differences between younger and older adult patients will be characterized, and then the problem of germline mutations in MDS will be briefly described.
At the end of the article, the possibilities of targeted treatment will be summarized as a hope for our patients.